

Initial Prior Authorization with Logic Uloric

Products Referenced by this Document

Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Uloric	febuxostat

Indications

FDA-approved Indications

Uloric is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

For the safe and effective use of allopurinol, see allopurinol prescribing information.

Limitations of Use

Uloric is not recommended for the treatment of asymptomatic hyperuricemia.

Screen out Code Logic

Include Rx and OTC products unless otherwise stated.

If the patient has filled a prescription for at least a 30 day supply of allopurinol within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial screen out logic criteria, then the claim will

Reference number(s)
540-D

reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

Coverage Criteria

Hyperuricemia

Authorization may be granted when the requested drug is being prescribed for the chronic management of hyperuricemia in an adult patient with gout when ONE of the following criteria are met:

- The patient has experienced an inadequate treatment response to a maximally titrated dose of allopurinol
- The patient has experienced an intolerance to allopurinol
- Treatment with allopurinol is contraindicated or inadvisable for the patient

Continuation of Therapy

Hyperuricemia

Authorization may be granted when the requested drug is being prescribed for the chronic management of hyperuricemia in an adult with gout when the following criteria is met:

- The patient has achieved or maintained a positive clinical response since beginning treatment with the requested drug

Duration of Approval (DOA)

- 540-D: DOA: 36 months

References

1. Uloric [package insert]. Lexington, Massachusetts: Takeda Pharmaceuticals America, Inc.; April 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed October 28, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 10/28/2024).

Reference number(s)
540-D

4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Rheumatol.* 2020;72(6):879-895.